Related Experiment Videos

Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy

Cristina Tau1, Carlos Mautalen, Cristina Casco

  • 1Metabolismo Cálcico y Oseo, Endocrinología, Buenos Aires, Argentina. cristinatau@uol.com.ar

Bone
|June 23, 2004
PubMed

Insights

Chronic idiopathic hyperphosphatasia (CIH), a rare bone disorder, can be effectively treated. Pamidronate therapy significantly improved a young girl's symptoms and normalized bone turnover markers.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Bone Disease
  • Rare Genetic Disorders

Background:

  • Chronic idiopathic hyperphosphatasia (CIH), also known as juvenile Paget disease, is a rare genetic disorder.
  • It is characterized by significantly increased bone turnover and progressive skeletal enlargement.

Observation:

  • A 6.5-year-old girl presented with fractures, short stature, delayed dental eruption, hair loss, gait abnormalities, and skeletal deformities.
  • She experienced progressive hearing loss, but other cranial nerves were unaffected.
  • Radiographs revealed generalized skeletal involvement, including osteoectasia, sclerosis, skull abnormalities, and vertebral compression.

Findings:

  • Elevated serum alkaline phosphatase, urinary hydroxyproline, and urinary CrossLaps confirmed high bone turnover.
  • Two years of cyclical intravenous and oral pamidronate, with calcium and vitamin D, led to substantial clinical and radiographic improvements.
  • Bone turnover markers normalized, indicating successful treatment of osteoblastic and osteoclastic activity.

Implications:

  • Pamidronate therapy offers a promising treatment for chronic idiopathic hyperphosphatasia.
  • Early intervention and sustained treatment can reverse skeletal abnormalities and normalize bone metabolism in affected children.
  • This case highlights the importance of recognizing CIH and initiating prompt management to improve patient outcomes.

Related Concept Videos

Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...